Necdet ALTINER
PIWI interacting RNAs (piRNAs) are the novel members of small non-coding RNAs which cannot produce any protein but are effective on transcription and posttranscriptional mechanisms of cells. Coumarin derivates can be used as a drug in various types of diseases. In this study we used an isoform of coumarin which is called 4-OH-Coumarin. In scientific literature, there is not enough researches about coumarin treatment in hepatocellular carcinoma. In this study, we aimed to determine the effect of 4-OH-Coumarin on piR-Hep-1 and piR-651 expressions of HePG2 cells. According to our previous study, the optimal concentration and time of 4-OHCoumarin was treated to HePG2 hepatocellular carcinoma cells. After treatment, total RNA was isolated and the expression changes of piR-Hep-1 and piR-651 was determined on these cells by using Real Time Polymerase Chain Reactions (RTPCR). According to our obtained data, statistically significant upregulation of piR-651 expressions was observed in 4-OH-Coumarin treated HePG2 cells compared to control (P<0.001). On the other hand, the expression of piR-Hep-1 did not affect from 4-OHCoumarin treatment statistically Notes: significant (P>0.05). In scientific literature, the expression patterns of piR-Hep-1 is not clear yet. In some types of cancer types, it was upregulated, but it was downregulated in some types of cancer types. Our results indicated that about 4-OHCoumarin is useless to determine the piR-Hep-1 expression pattern. This result is significant to clarify the relationship between piR-HeP-1 and 4-OH-Coumarin treatment. Generally, piR-651 is downregulated in circulating tumor cells. Our results indicated that 4-OH-Coumarin treatment on HePG2 cells might be effective to regulate the effect of piR651. All these data indicate that some of piRNAs might have special expression patterns in hepatocellular carcinoma and these expression patterns can be regulated by treated natural compounds which are used to inhibit the effects of cancer cells.
Teile diesen Artikel